Metachronous Contralateral Recurrence in Upper Tract Urothelial Carcinoma: A Multi-Institutional Competing-Risks Analysis From the ROBUUST 3.0 Registry

Résumé fourni par la source

INTRODUCTION: The purpose of this study was to define the incidence and predictors of metachronous contralateral recurrence in upper tract urothelial carcinoma and develop a risk score for tailored surveillance. METHODS: . Patients were stratified into low (0 points), intermediate (1-2 points), and high (3 points) risk. Cumulative incidence was estimated using competing-risks regression models, accounting for death and distant metastasis and internally validated using a cause-specific proportional hazards model. RESULTS: < .001). High-risk patients faced an estimated 17-fold increased hazard vs low-risk patients. The model demonstrated excellent discriminative accuracy (Concordance Index 0.81). CONCLUSIONS: Contralateral recurrence is rare but heavily dependent on prior bladder cancer, multifocality, and impaired renal function. Our internally validated risk score accurately stratifies patients, facilitating surveillance de-escalation for low-risk individuals and intensive monitoring for high-risk patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.